Alcobra Ltd. to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Host Corporate Update Conference Call & Webcast on February 17

TEL AVIV, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.

Conference Call & Webcast
Wednesday, February 17, 2016 @ 8:30am Eastern Time
Replays available through March 2, 2016

About Alcobra

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Source:Alcobra Ltd.